)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Santhera Pharmaceuticals
Santhera Pharmaceuticals (SANN) investor relations material
Santhera Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary23 Sep, 2025
Executive summary
AGAMREE, a differentiated corticosteroid for Duchenne muscular dystrophy (DMD), achieved rapid global rollout with approvals and launches in the US, Europe, UK, China, and Hong Kong, and strong adoption in Germany, Austria, and the US.
Market share exceeded 50% in Austria and reached 40% in Germany among steroid-using DMD patients, with rapid uptake in the UK and over 250 patients treated in China since launch.
Global AGAMREE sales (including partners) exceeded USD 100 million over four quarters, triggering a USD 25 million milestone payment.
New CHF 20 million financing was secured in September 2025, extending cash runway to mid-2026 and supporting inventory build-up for surging demand.
Executive and board changes included the appointment of a new CFO and board member in 2025.
Financial highlights
Total revenues for H1 2025 were CHF 24 million, a 70% year-over-year increase, driven by strong product sales and royalties.
Product revenues reached CHF 11.6 million, up 76% from the prior year, mainly from Germany, Austria, and the UK.
Revenues from US and Chinese partners totaled CHF 12.4 million, up 63% year-over-year.
Operating expenses for H1 2025 were CHF 27.3 million (CHF 25 million excluding share-based payments), in line with guidance.
Operating loss was CHF 35.4 million; excluding the USD 25 million milestone payment, the loss was reduced by CHF 2.6 million from last year.
Outlook and guidance
Full-year 2025 revenue guidance raised to exceed CHF 65–70 million, reflecting strong growth in direct and partner markets.
2028 revenue guidance maintained at EUR 150 million from direct and partner markets, excluding milestones.
2030 direct market sales expected to exceed EUR 150 million, with additional upside from royalties and partners.
Operating expenses for 2025 and beyond expected in the CHF 50–55 million range, excluding non-cash share compensation.
Cash-flow break-even targeted for mid-2026.
Liquidity outlook to mid-2026
GUARDIAN data impact on EU launches?
Portfolio expansion strategy beyond DMD
What drove the need for additional capital?
What will GUARDIAN study data reveal?
Future strategy beyond AGAMREE expansion?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Santhera Pharmaceuticals
Next Santhera Pharmaceuticals earnings date
H2 202529 Apr, 2026
Santhera Pharmaceuticals
Next Santhera Pharmaceuticals earnings date
H2 202529 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage